Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H23NO2 |
Molecular Weight | 261.3593 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1CCCCN1CCCOC(=O)C2=CC=CC=C2
InChI
InChIKey=YQKAVWCGQQXBGW-UHFFFAOYSA-N
InChI=1S/C16H23NO2/c1-14-8-5-6-11-17(14)12-7-13-19-16(18)15-9-3-2-4-10-15/h2-4,9-10,14H,5-8,11-13H2,1H3
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/18138121Curator's Comment: Description was created using several sources including:
http://www.annualreviews.org/doi/abs/10.1146/annurev.pa.09.040169.002443?journalCode=pharmtox.1; http://www.ncbi.nlm.nih.gov/pubmed/15402120; http://www.ncbi.nlm.nih.gov/pubmed/18149171; http://www.ncbi.nlm.nih.gov/pubmed/7635175; http://purl.bioontology.org/ontology/NDDF/003425; http://www.accessdata.fda.gov/scripts/animaldrugsatfda/details.cfm?dn=040-123
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm467373.pdf;
https://books.google.com/books?id=79BGAQAAMAAJ&pg=PA263&lpg=PA263&dq=METYCAINE+was+manufactured&source=bl&ots=-PQVR0IZgE&sig=9DfpIP-V1qufWzn5gmpEzdVfYVY&hl=en&sa=X&ved=0ahUKEwjr-qjk2rHLAhUJ8CYKHTG0DdkQ6AEILzAE#v=onepage&q=METYCAINE%20was%20manufactured&f=false
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18138121
Curator's Comment: Description was created using several sources including:
http://www.annualreviews.org/doi/abs/10.1146/annurev.pa.09.040169.002443?journalCode=pharmtox.1; http://www.ncbi.nlm.nih.gov/pubmed/15402120; http://www.ncbi.nlm.nih.gov/pubmed/18149171; http://www.ncbi.nlm.nih.gov/pubmed/7635175; http://purl.bioontology.org/ontology/NDDF/003425; http://www.accessdata.fda.gov/scripts/animaldrugsatfda/details.cfm?dn=040-123
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm467373.pdf;
https://books.google.com/books?id=79BGAQAAMAAJ&pg=PA263&lpg=PA263&dq=METYCAINE+was+manufactured&source=bl&ots=-PQVR0IZgE&sig=9DfpIP-V1qufWzn5gmpEzdVfYVY&hl=en&sa=X&ved=0ahUKEwjr-qjk2rHLAhUJ8CYKHTG0DdkQ6AEILzAE#v=onepage&q=METYCAINE%20was%20manufactured&f=false
Piperocaine (Metycaine) is a local anesthetic drug. It is an ester and primarily is a sodium channel blocker. Piperocaine can partially inhibit dopamine. It is known as a alpha-1-proteinase inhibitor. Used in the form of its hydrochloride as a local or spinal anesthetic and in dental anesthesia. Can cause toxic reactions. Piperocaine Hydrochloride is in the list of Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, FDA Act. Piperocaine hydrochloride is a small, white odorless crystals or a white crystalline powder, stable in air, freely soluble in water, alcohol and chloroform.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3350224 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1922660 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Metycaine Hydrochloride Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
60 mg single, dental Recommended Dose: 60 mg Route: dental Route: single Dose: 60 mg Co-administed with:: epinephrine(1:60,000; single) Sources: |
unhealthy, 10-90 n = 57 Health Status: unhealthy Condition: dental surgery Age Group: 10-90 Sex: M+F Population Size: 57 Sources: |
Other AEs: Tremor, Tremor... Other AEs: Tremor (slight, 28.1%) Sources: Tremor (moderate, 3.5%) Sweating (slight, 17.5%) Sweating (moderate, 1.8%) Nervousness (slight, 29.8%) Nervousness (moderate, 5.3%) Nervousness (extreme, 8.8%) Faintness (5.3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Faintness | 5.3% | 60 mg single, dental Recommended Dose: 60 mg Route: dental Route: single Dose: 60 mg Co-administed with:: epinephrine(1:60,000; single) Sources: |
unhealthy, 10-90 n = 57 Health Status: unhealthy Condition: dental surgery Age Group: 10-90 Sex: M+F Population Size: 57 Sources: |
Nervousness | extreme, 8.8% | 60 mg single, dental Recommended Dose: 60 mg Route: dental Route: single Dose: 60 mg Co-administed with:: epinephrine(1:60,000; single) Sources: |
unhealthy, 10-90 n = 57 Health Status: unhealthy Condition: dental surgery Age Group: 10-90 Sex: M+F Population Size: 57 Sources: |
Sweating | moderate, 1.8% | 60 mg single, dental Recommended Dose: 60 mg Route: dental Route: single Dose: 60 mg Co-administed with:: epinephrine(1:60,000; single) Sources: |
unhealthy, 10-90 n = 57 Health Status: unhealthy Condition: dental surgery Age Group: 10-90 Sex: M+F Population Size: 57 Sources: |
Tremor | moderate, 3.5% | 60 mg single, dental Recommended Dose: 60 mg Route: dental Route: single Dose: 60 mg Co-administed with:: epinephrine(1:60,000; single) Sources: |
unhealthy, 10-90 n = 57 Health Status: unhealthy Condition: dental surgery Age Group: 10-90 Sex: M+F Population Size: 57 Sources: |
Nervousness | moderate, 5.3% | 60 mg single, dental Recommended Dose: 60 mg Route: dental Route: single Dose: 60 mg Co-administed with:: epinephrine(1:60,000; single) Sources: |
unhealthy, 10-90 n = 57 Health Status: unhealthy Condition: dental surgery Age Group: 10-90 Sex: M+F Population Size: 57 Sources: |
Sweating | slight, 17.5% | 60 mg single, dental Recommended Dose: 60 mg Route: dental Route: single Dose: 60 mg Co-administed with:: epinephrine(1:60,000; single) Sources: |
unhealthy, 10-90 n = 57 Health Status: unhealthy Condition: dental surgery Age Group: 10-90 Sex: M+F Population Size: 57 Sources: |
Tremor | slight, 28.1% | 60 mg single, dental Recommended Dose: 60 mg Route: dental Route: single Dose: 60 mg Co-administed with:: epinephrine(1:60,000; single) Sources: |
unhealthy, 10-90 n = 57 Health Status: unhealthy Condition: dental surgery Age Group: 10-90 Sex: M+F Population Size: 57 Sources: |
Nervousness | slight, 29.8% | 60 mg single, dental Recommended Dose: 60 mg Route: dental Route: single Dose: 60 mg Co-administed with:: epinephrine(1:60,000; single) Sources: |
unhealthy, 10-90 n = 57 Health Status: unhealthy Condition: dental surgery Age Group: 10-90 Sex: M+F Population Size: 57 Sources: |
Sample Use Guides
For continuous caudal analgesia in obstetrics initial dose of 30 ml of 1 and 1.5 % metycaine produced analgesia as high as the line midway between the pubis and the umbilicus and relieved the pains of labor.
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7635175
At a maximum concentration of 100 uM, the ester containing local anesthetics procaine, tetracaine, piperocaine and the amide containing local anesthetic dibucaine and bupivacaine partially inhibited dopamine uptake by 47-70%
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
33752
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | RxNorm | ||
|
205-262-1
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
DTXSID8048315
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
F66XUI6GZL
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
C90654
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
SUB09871MIG
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
4176
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
10782
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
m8857
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
PIPEROCAINE
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL127865
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
100000081966
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
C023039
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY | |||
|
136-82-3
Created by
admin on Fri Dec 15 15:17:41 GMT 2023 , Edited by admin on Fri Dec 15 15:17:41 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)